Navigation Links
Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results
Date:8/22/2007

SEATTLE, Aug. 22 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that results from a series of HIV vaccine Phase 2a clinical trials, using a plasmid DNA (pDNA) vaccine developed by the NIH Vaccine Research Center and manufactured by Vical, reinforced previously reported Phase 1 conclusions that a "DNA prime-adenoviral vector boost" vaccine regimen was safe and well-tolerated, and was effective in inducing T-cell immune responses in up to 70% of the vaccine recipients.

"These recent vaccine trials contribute to the growing body of knowledge demonstrating plasmid DNA priming as a key factor in achieving significant immune responses against HIV, a particularly difficult target pathogen, bringing us one step closer to evaluating the effectiveness of a prime-boost HIV vaccine regimen in a prophylactic setting," said Vijay B. Samant, Vical's President and Chief Executive Officer. "The latest International AIDS Vaccine Initiative (IAVI) listing of ongoing preventive HIV vaccine clinical trials shows that more than half use pDNA either alone or in combination with other vaccine modalities. We are very pleased that DNA technology is an integral part of the effort to address this high priority global health problem."

The trials involved priming an immune response with three doses of a pDNA vaccine over a two month period, based on Vical's proprietary DNA technology, and boosting the response with a single dose of adenoviral vector vaccine at six months. The three trials, collectively known as TRIAD, were conducted by the National Institute of Allergy and Infectious Diseases (NIAID) HIV Trials Vaccine Network (HVTN), the IAVI, and the U.S. Military HIV Research Program (USMHRP). Richard Koup, M.D., Chief of Immunology at the Dale and Betty Bumpers Vaccine Research Center (VRC), NIAID, National Institutes of Health (NIH), highlighted TRIAD summary results and conclusions in an oral presentation, "Update on safety and immunogenicity
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... VICL ) today announced the receipt of ... for costs associated with the ongoing Allovectin-7(R),Immunotherapeutic for ... is funding the Phase 3 pivotal trial of ... scheduled series of,cash payments and equity investments totaling ...
... Atrial ... Fibrillation Patients, CARLSBAD, Calif., Jan. 16 ... ever U.S.,Investigational Device Exemption (IDE) clinical trial for interventional,treatment of chronic ... to proceed with the pivotal phase of the,study is based on ...
Cached Medicine Technology:Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 2Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial 3FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 2FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial 3
(Date:9/2/2014)... (PRWEB) September 02, 2014 Smile Squared, ... their product offering to include a US-made toothbrush. For ... child without one. , “Smile Squared was created by ... clinic in Guatemala,” said Eric Cope, President of Smile ... sometimes severe dental problems. But many of the same ...
(Date:9/2/2014)... Spain Tuesday 2 September 2014: Digoxin may increase ... (AF) by approximately 20%, according to results from the ... Dr Manesh Patel, director of interventional cardiology and catheterisation ... Carolina, US. The findings suggest that caution may be ... further studies are needed to confirm the observations. , ...
(Date:9/2/2014)... The fact that mechanical heart valves increase risks during ... the ROPAC registry presented for the first time today ... Jolien W. Roos-Hesselink, co-chair with Professor Roger Hall of ... of pregnant women with a mechanical heart valve died ... Registry Of Pregnancy And Cardiac disease (ROPAC) is an ...
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and home medical ... of its new office to be located in Greer, ... Suite D, Greer, SC 29651. This new location will ... convenient location in the Greenville area. , “This is ... hospitals and patients we serve, to ensure that we ...
(Date:9/2/2014)... 2014 Attorney Robert M. Higgins ... of the Year" for Medical Malpractice Law - ... Boston, and has been selected for inclusion in The Best ... in each practice area and designated metropolitan area is honored ... voting averages received during the peer-review assessments. , The ...
Breaking Medicine News(10 mins):Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2
... the process of developing a vaccine called Gardasil against ... is being sought by the organization in Europe and ... MSD has to approve of the marketing authorization for ... to have a decided advantage over GlaxoSmithKline’s Cervarix. Both ...
... (PCRM) has developed an in-house animal serum free diabetes test ... by Linco Research. PCRM started to initiate the development of ... that it is not possible to develop the test kit ... kit uses synthetic medium and the cost and accuracy is ...
... treated with 500 mcg of Aranesp (Darbepoetin alfa) for ... in 70% of patients. //The new drug Aranesp is ... trial with 200 low-risk MDS patients who were administered ... is a pre-leukemia stage in which the bone marrow ...
... conducted by George S. Zubenko, MD, PhD, Professor of Psychiatry ... that genes relating to aging with preserved mental capacity have ... kind and was funded by National Institutes of Health (NIH). ... years old or above. There were equal number of men ...
... Botulinum toxin A or Botox as it is popularly tagged ... for erasing wrinkles and making the facial skin appear fresh ... of Cosmetic Dermatology says that there is more to botox ... BTXA as it is called in medical parlance can also ...
... body thinking that it will fetch happiness. A study has ... mental suffering and woes, and they are far from being ... chances of slim people committing suicide appear to be greater ... ,The research was also extended to studying the European population, ...
Cached Medicine News:Health News:Genetics of Ageing with Preserved Mental Capacity. 2
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medicine Products: